Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part IV
Emmanuel J. Favaloro
DOI: https://doi.org/10.1055/s-0044-1785652
2024-04-09
Seminars in Thrombosis and Hemostasis
Abstract:Welcome to another issue of Seminars in Thrombosis and Hemostasis (STH). This one is another very special issue, being the fourth of a series of issues we are publishing to celebrate the 50 th anniversary of the journal. As explained more fully in a prior editorial,[1] STH has been part of the Thrombosis and Hemostasis landscape for 50 years. STH was first published in 1974, and so turns 50 in 2024. The current issue of STH marks the fourth and final of these special issues and further helps celebrate the 50 th year "birthday" for STH. STH was founded by Eberhard F. Mammen ([Fig. 1]). The journal started small, with only two issues and some 210 printed pages in its first year. The journal has grown over the years and now publishes 8 issues and some 900 printed pages, per year, having also achieved a landmark of just over 1,000 printed pages in 2020 ([Fig. 2]). The number of printed pages in 2021 and 2022 were just under 1,000, being an identical 994 in each year. The year 2023 saw a return to more normal publication metrics, with 866 printed pages. However, 2024 will likely return us to the >1,000 printed pages mark, given the current count is >500 printed pages at end of issue no. 3. This "excess" of printed pages is in large part due to the celebratory historical connection, as further explained below. The number of articles published per year according to PubMed also seems to be increasing ([Fig. 3]), although the contribution of manuscripts published as early on line (eFirst) needs to be recognized in this tally. Thus, a similar number of articles are actually published each year in the print issues, but an increasing number of publications are released early online. The current issue, like the first three in this series,[2] [3] [4] contains a range of material related to the broad concepts of thrombosis and hemostasis with a historical connection. The issue begins with an overview of the development of a coagulation disorders unit in Helsinki,[5] Finland, which provides 24/7 services for local and national hospitals and colleagues upon requests, regarding bleeding and thrombosis diagnostics and management, including follow-up. It is likely that this specific unit mirrors those of other similar units set up in other localities. The Nordic unit has a tight connection between the clinic and laboratory, and its maintenance and sharing knowledge and observations have been priorities for the past 20 or more years and will continue to be of major importance into the future. The consultation service is provided by phone during daytime and on-call hours and also in written form sent electronically to the consulting stakeholders. Thrombosis and hemostasis-targeted outpatient clinics are also available for patients referred to the center. Writing local guidance and official guidelines, Nordic, European, and international collaboration, and educational activities including social communication are critical elements for the Nordic Coagulation Disorders Unit. Alertness to acute coagulation abnormalities, such as occurred during coronavirus disease 2019 and vaccine-induced thrombosis and thrombocytopenia, and development of strategies to manage cross-disciplinary problems are topics that call upon broad networking. The Nordic community has an ongoing historical meeting, which has been circulating among coagulation centers for the past 56 years. At the European level, the European Association of Haemophilia and Allied Disorders focuses on bleeding disorders and their management, including safety surveillance. The International Society on Thrombosis and Haemostasis offers excellent basic and clinical benchmarks for any Coagulation Disorders Unit. The authors hope that their description of the development and implementation of their Coagulation Disorders Unit in Helsinki achieves international interest and broadens international collaboration. Finally, they congratulate STH on its great contributions around the globe and for providing a vivid forum to foster the discipline of thrombosis and hemostasis. The next few submissions largely relate to bleeding disorders and their management. First, Chandran and colleagues discuss aspects of the management of hemophilia A,[6] which has undergone a remarkable revolution, in line with technological advancement, in recent years. Once, the primary concern associated with Factor VIII (FVIII) concentrates was the risk of infections, which is now almost resolved by advanced blood screening and viral inactivation methods. Improving patients' compliance with prophylaxis then became a key focus, as this can lead to improved health outcomes and reduce health care costs in the long term. Recent bioengineering research has been directed toward prolonging the recombinant FVIII (rFVIII) coagulant activity and synthesizing higher FVIII yields. As an outcome, B-domain deleted, poly -Abstract Truncated-
peripheral vascular disease,hematology